Subtype: Some subtypes of NSCLC, such as large cell carcinoma, grow and spread more quickly than others and can be more difficult to treat. Age: Younger people generally have a better prognosis ...

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

Advanced NSCLC research has led to improved outcomes for people like May over the past decade, 1 yet lung cancer, including NSCLC, remains the most commonly diagnosed cancer in the world 2 and the ...

BRAF-positive NSCLC is an uncommon or rare subtype of lung cancer. The targeted treatments for this subtype of cancer may provide more effective treatment compared to non-specific treatments, such ...

Large-cell undifferentiated carcinoma makes up about 10 to 15 percent of all NSCLC lung cancer cases. It can start in any part of the lung and spreads faster than other NSCLC subtypes.

The biomarker focused Phase 1b/2 clinical trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with the immune checkpoint inhibitors nivolumab and ipilimumab in ...

Subtype: Some subtypes of NSCLC, such as large cell carcinoma, grow and spread more quickly than others and can be more difficult to treat. Age: Younger people generally have a better prognosis ...

The biomarker focused Phase 1b/2 clinical trial is designed to target high-risk NSCLC subtypes by evaluating LP-184 in combination with the immune checkpoint inhibitors nivolumab and ipilimumab in ...